New gene therapy slows progression of Huntington's disease
Digest more
It's a test of CEO Bill Anderson's development credentials as patent expiries on blockbuster drugs threaten the group's long-term growth projects.
A single one-time gene therapy could free patients with α-thalassemia, a rare and debilitating blood disorder, from the burden of lifelong transfusions.